Lars Hellerung Christiansen
Co-Founder @ Zealand Pharma
Lars Hellerung Christiansen is a Series A investor at Zealand Pharma focused on Pharmaceutical. Lars Hellerung Christiansen
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Lars Hellerung Christiansen invests in
Stages Lars Hellerung Christiansen invests in
Countries Lars Hellerung Christiansen invests in
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neumirna Therapeutics
|
Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions. | $20.6M / Series A / Jan 08, 2025 |
Co-Investors
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare andBoehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
Zealand Pharma Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Steensberg
Chief Executive Officer
|
|||
Andrew Parker
Chief Scientific Officer, Executive Vice-President, Head of Research & External Innovation
|
|||
Daan Ellens
Chairman of the Supervisory Board
|
|||
|
Lars Hellerung Christiansen
Co-Founder
|
|||
Marie Skovgaard
Director of Medicinal Chemistry
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Lars Hellerung Christiansen invest in?
Lars Hellerung Christiansen invests primarily in Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Lars Hellerung Christiansen last invest?
The most recent investment recorded for Lars Hellerung Christiansen closed in Jan 2025. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
